MBTPS1

(redirected from S1p)
Also found in: Acronyms.

MBTPS1

A gene on chromosome 16q24 that encodes a sterol-regulated subtilisin-like serine protease, which cleaves ER membrane-bound sterol regulatory element-binding proteins (SREBPs), releasing transcriptionally active SREBP fragments for translocation to the nucleus.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
The majority of S1P is stored in platelets and erythrocytes.
[57] AD, Alzheimer's disease; BCG, bacillus Calmette-Guerin; BPND, binding potential; DVR, distribution volume ratio; EAE, experimental autoimmune encephalitis; GA, glatiramer acetate; MS, multiple sclerosis; MSA, multiple system atrophy, NAWM, normal appearing white matter; PD, Parkinson's disease; RRMS, relapsing-remitting multiple sclerosis; S1P, sphingosine 1-phosphate; [V.sub.T], total distribution volume.
SP and S1P plasma concentration measurements were performed as previously described [31, 32].
Germain, "Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo," The Journal of Experimental Medicine, vol.
Ralinepag is a Phase 3-ready next-generation, oral, selective prostacyclin receptor (IP) agonist for the treatment of pulmonary arterial hypertension (PAH), and etrasimodis a Phase 2 oral, next-generation, S1P receptor modulator, that is being evaluated for multiple autoimmune diseases, including ulcerative colitis.
Congenital sphingosine1phosphate (S1P) lyase deficiency due to biallelic mutations in the SGPL1 gene has been described, in association with PAI and steroid-resistant nephrotic syndrome (30,31,32).
But unlike natural ceramides, the compounds in the treatment do not breaks down into another molecule, known as sphingosine-1-phosphate or S1P, that promotes inflammation.
The membrane-bound transcription factor site-1 protease (MBTPS1) (also known as serine protease 1: S1P), a serine protease involved in SREBF1 activation, was predicted to be activated in all treatments as expected although not always in the top 20 (Inoue et al.
Celgene's Phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) [beta]-1a (Avonex).
However, recent studies point to important proapoptotic functions for metabolites of the sphingolipid degradation pathway, such as sphingosine-1-phosphate (S1P) or hexadecenal [17,18].